CJC-1295 + Ipamorelin
Also sold as CJC/Ipa, GHRH/GHRP Stack.
- Half-life
- 2 h
- Steady state
- ~0 d
- Class
- GH
- Category
- Peptide
Published population averages. Steady state is the usual five half-life rule of thumb, not a measurement. See peptide half-life, explained.
Overview
The CJC-1295/Ipamorelin combination is the most widely used growth hormone (GH)-releasing peptide stack. CJC-1295 (Modified GRF 1-29) is a GHRH analogue that stimulates pulsatile GH release, while Ipamorelin is a selective ghrelin receptor (GHSR) agonist. Together, they produce synergistic GH elevation with minimal side effects compared to direct HGH use.
How it works
CJC-1295 (no DAC) binds GHRH receptors on anterior pituitary somatotrophs, initiating GH pulse release. Ipamorelin binds ghrelin/GHSR receptors on the same cells, amplifying the GH pulse amplitude. Combined, they replicate natural pulsatile GH secretion at higher amplitude while preserving the body's negative feedback. Ipamorelin is uniquely selective — it doesn't raise cortisol, prolactin, or acetylcholine significantly.
Half-life and peak
CJC-1295 (no DAC): half-life ~30 minutes. Ipamorelin: half-life ~2 hours. Combined GH pulse peaks at 30–45 minutes and elevates GH/IGF-1 for 3–4 hours. Typically dosed 2–3 times daily (pre-sleep most important).
What it is studied for
Growth hormone augmentation, body composition improvement, anti-aging, sleep quality, recovery from training, IGF-1 optimization without supraphysiologic HGH levels.
Research status
Both peptides have published Phase 1–2 human safety data. CJC-1295 with DAC was studied by ConjuChem but development paused. Ipamorelin was studied by Helsinn. Neither is FDA-approved. Widely used off-label in anti-aging clinics.
Sources
- Modified GRF(1-29) pharmacology — Endocrine Reviews · pubmed.ncbi.nlm.nih.gov
- Ipamorelin selectivity profile — European J. Endocrinology · doi.org
- GH secretagogues review — Growth Hormone & IGF Research · pubmed.ncbi.nlm.nih.gov
- CJC-1295 PK in healthy subjects · doi.org
- Ipamorelin pharmacokinetics — Eur. J. Drug Metab. · pubmed.ncbi.nlm.nih.gov
Educational reference only. This page describes what is published about a compound; it is not medical advice, not a recommendation to take anything, and not a dosing guide. Several compounds in this catalog are investigational and are not approved medicines. Talk to a doctor.